← Human Trials & Peer-Reviewed Studies
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Plain-language guide to NCT06222437: phase 1 interventional trial of Semaglutide. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06222437
- Phase
- phase 1
- Status
- withdrawn
- Start
- 2026-02
- Completion (planned or actual)
- 2026-02
- Participants
- n/a (actual)
- Design
- na, open label (everyone knows who gets what), treatment
- Conditions studied
- Polycystic Ovary Syndrome
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 1) is built around Semaglutide.
It had 1 arm (groups): Protocol group (experimental).
PCOS women in the age 18 to 45 years.
The registry classes the interventions as drug.
More on the Plan
The study mainly focused for the following objectives: To determine the effect of semaglutide on ovulation and menstrual regularity.
To determine the effect of semaglutide on androgen levels, namely testosterone, sex hormone binding globulin, and changes in hirsutism.
To determine changes in weight, body mass index (BMI), and Glycated Hemoglobin( HbA1c) with semaglutide therapy.
Who Took Part
It was open to women only aged from 18 years up to 45 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Body mass index(BMI) \> 30. Diagnosis of PCOS. Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone.
The full record lists 4 inclusion and 7 exclusion criteria; among the exclusions: medications excluded: any hormone-containing contraceptive - oral contraceptive pills, progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device; letrozole, clomiphene citrate, fsh therapy; androgen receptor blockers.
How the Study Was Run
The set-up was single-group and open-label.
Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2026-02 with completion listed for 2026-02.
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: Number of days on therapy (time frame: 4 weeks).
It also tracked 2 secondary outcomes, for example measure the Weight in kilograms and Numbers of days with exercise changes.
What This Means in Plain Language
Put simply, this is a phase 1 trial of Semaglutide in people.
It was withdrawn before enrolling anyone; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.